# Author self-check

State: author self-check only; independent acceptance has not occurred.

| Check | Evidence | Result and limit |
| --- | --- | --- |
| Required task scope represented | `WORKFLOW.md` delivery contract and stages | Includes 42 dates, 12×8 pairs, point forecast, nominal 90% interval, integer plan, loss terms, resource caps, comparison, paper and limits. |
| C13 reusable-flow requirements represented | Role table, input/output interfaces, branch gates, failure paths, first smoke and acceptance sections | Design review by author only; no independent reading yet. |
| Source-time rules and revision handling represented | Stage 1, Stage 4, residual-lineage interface | Full production backtest not performed. |
| Probe artifact interfaces | `probe-output-v2/predictions.csv`, `replenishment.csv`, `scenarios.csv`, `feature_lineage.csv`, `summary.json` | Probe produced 96 unique keyed rows each for one date and 14 complete daily scenarios; not the 4,032-row final product. The original first-run outputs remain under `probe-output/`; its pre-lineage-export source variant is retained at `versions/probe-v1.py`. |
| Daily constraints and solver output | Probe summary: 1,600 units, 5,584 yuan, solver status Optimal, zero reported gap | Author-side recomputation in `selfcheck.json` gives 609.8701058186389 yuan expected scenario loss, within numeric tolerance of solver summary. This remains one date and one 14-vector scenario sample; independent acceptance is pending. |
| Telemetry integrity | `INPUTS.json`, probe summary | Actual model/tokens/cost unknown; not inferred. |
| Write boundary | Files authored under `runs/R23/design/` only | Must be confirmed by the parent before freezing; no shared TODO/checkpoint or product skill writes. |
| Command completion evidence | Unique receipts under `receipts/` | Successful and failed attempts are retained separately. Each shell command reached a terminal exit; final receipt/path inventory must be inspected before freeze. |

No result in this file claims production completion, validated 90% coverage, model superiority, paper acceptance, or an independent verdict.
